

Grazia Graziani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2500796/publications.pdf>

Version: 2024-02-01

154
papers

5,496
citations

81900

39
h-index

102487

66
g-index

155
all docs

155
docs citations

155
times ranked

7580
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	7.1	43
2	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. , 2022, 236, 108106.		16
3	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.9	3
4	Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. <i>Biomolecules</i> , 2022, 12, 315.	4.0	3
5	High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients. <i>Cancers</i> , 2021, 13, 1428.	3.7	17
6	hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF. <i>Pathology and Oncology Research</i> , 2021, 27, 612375.	1.9	4
7	Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 385-397.	2.5	7
8	Saffron and Its Major Ingredientsâ€™ Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability. <i>Molecules</i> , 2021, 26, 3855.	3.8	64
9	At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 4852.	3.7	15
10	The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021, 10, 466.	2.4	7
11	VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 320.	8.6	23
12	Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 465-475.	3.6	34
13	Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 3401.	3.7	39
14	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2020, 180, 114169.	4.4	26
15	PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8214.	4.1	25
16	Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. <i>Nanotechnology</i> , 2020, 31, 382001.	2.6	30
17	Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. <i>Pharmacological Research</i> , 2020, 159, 104957.	7.1	22
18	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62

#	ARTICLE	IF	CITATIONS
19	Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1388.	4.1	127
20	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	3.3	3
21	Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165793.	3.8	11
22	Vascular endothelial growth factor receptor 1 in glioblastoma-associated microglia/macrophages. <i>Oncology Reports</i> , 2020, 43, 2083-2092.	2.6	10
23	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. <i>Chemotherapy</i> , 2019, 64, 62-80.	1.6	34
24	Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells. <i>Chemotherapy</i> , 2019, 64, 138-145.	1.6	4
25	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019, 11, 1373.	3.7	13
26	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019, 167, 133-148.	4.4	19
27	Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. <i>Pharmacological Research</i> , 2018, 131, 1-6.	7.1	5
28	Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells. <i>Oncology Reports</i> , 2018, 39, 2261-2269.	2.6	3
29	Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence. <i>Chemotherapy</i> , 2018, 63, 64-75.	1.6	11
30	The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF- κ B activation. <i>Cancer Letters</i> , 2018, 423, 127-138.	7.2	22
31	EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 743-752.	1.2	210
32	The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 77-86.	2.5	24
33	Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. <i>Nutrients</i> , 2018, 10, 1756.	4.1	178
34	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.	3.7	154
35	Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. <i>Pharmacological Research</i> , 2018, 136, 97-107.	7.1	126
36	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3626-3635.	6.4	24

#	ARTICLE	IF	CITATIONS
37	The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 106.	8.6	36
38	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. <i>Oncotarget</i> , 2017, 8, 13223-13239.	1.8	30
39	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 32550-32565.	1.8	47
40	Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. <i>Oncotarget</i> , 2017, 8, 66833-66848.	1.8	17
41	Modulation of GDF11 expression and synaptic plasticity by age and training. <i>Oncotarget</i> , 2017, 8, 57991-58002.	1.8	14
42	Exploiting Microglial Functions for the Treatment of Glioblastoma. <i>Current Cancer Drug Targets</i> , 2017, 17, 267-281.	1.6	40
43	Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes. <i>Translational Cancer Research</i> , 2017, 6, S1101-S1103.	1.0	0
44	Editorial. <i>Chemotherapy</i> , 2016, 61, 1-2.	1.6	0
45	Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. <i>Nutrients</i> , 2016, 8, 744.	4.1	76
46	Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. <i>International Journal of Oncology</i> , 2016, 48, 1581-1589.	3.3	34
47	EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. <i>Neuro-Oncology</i> , 2016, 18, 1644-1655.	1.2	78
48	Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. <i>Oncotarget</i> , 2016, 7, 72868-72885.	1.8	25
49	Neuropilin-1 as Therapeutic Target for Malignant Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 125.	2.8	61
50	Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of $\alpha_5\beta_1$ integrin. <i>International Journal of Cancer</i> , 2015, 136, E545-58.	5.1	49
51	Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, P6.	4.4	1
52	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. <i>Biochemical Pharmacology</i> , 2015, 95, 16-27.	4.4	29
53	BRCA1, PARP1 and γ H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 462-472.	3.8	53
54	Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 71.	8.6	3

#	ARTICLE	IF	CITATIONS
55	Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. <i>BMC Cancer</i> , 2014, 14, 151.	2.6	64
56	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. , 2014, , 233-258.		0
57	MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 117-125.	2.3	14
58	Challenging resistance mechanisms to therapies for metastatic melanoma. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 656-666.	8.7	90
59	Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Ligand Triggering Upregulates Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 and Promotes Leukocyte Adhesion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 164-172.	2.5	29
60	PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. <i>Frontiers in Oncology</i> , 2013, 3, 279.	2.8	19
61	Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. <i>Oncology Reports</i> , 2013, 30, 2887-2896.	2.6	20
62	Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. <i>International Journal of Oncology</i> , 2013, 43, 210-218.	3.3	10
63	PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage. <i>PLoS ONE</i> , 2013, 8, e72169.	2.5	70
64	Abstract C09: Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition. , 2013, , .		0
65	Targeted Therapy for Brain Tumours: Role of PARP Inhibitors. <i>Current Cancer Drug Targets</i> , 2012, 12, 218-236.	1.6	23
66	Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. <i>Pharmacological Research</i> , 2012, 65, 9-22.	7.1	119
67	NF- κ B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. <i>Journal of Translational Medicine</i> , 2012, 10, 252.	4.4	32
68	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. <i>PLoS ONE</i> , 2012, 7, e51563.	2.5	78
69	The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. <i>European Journal of Cancer</i> , 2011, 47, 1219-1230.	2.8	32
70	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. <i>British Journal of Dermatology</i> , 2011, 164, 1061-1070.	1.5	25
71	Common fragile sites in colon cancer cell lines: Role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 712, 40-48.	1.0	11
72	Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. <i>Biochemical Pharmacology</i> , 2011, 81, 194-202.	4.4	18

#	ARTICLE	IF	CITATIONS
73	Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-27.	3.3	4
74	Abstract C51: High sensitivity of testicular germ cell tumors to PARP inhibitor olaparib alone and in combination with cisplatin. , 2011, , .		0
75	Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF- κ B. <i>International Journal of Oncology</i> , 2011, 38, 241-7.	3.9	9
76	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. <i>Oncogene</i> , 2010, 29, 6280-6293.	5.9	103
77	Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. <i>Current Cancer Drug Targets</i> , 2010, 10, 368-383.	1.6	18
78	Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. <i>Anticancer Research</i> , 2010, 30, 4721-30.	1.1	5
79	Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. <i>Nucleic Acids Research</i> , 2009, 37, 6849-6858.	14.5	29
80	Recent Approaches to Improve the Antitumor Efficacy of Temozolomide. <i>Current Medicinal Chemistry</i> , 2009, 16, 245-257.	2.4	80
81	Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 664, 39-47.	1.0	6
82	Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. <i>International Journal of Oncology</i> , 2009, 34, 861-72.	3.3	12
83	Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. <i>European Journal of Cancer</i> , 2008, 44, 1302-1314.	2.8	40
84	Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. <i>European Journal of Cancer</i> , 2008, 44, 1914-1921.	2.8	21
85	The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. <i>Oncology Reports</i> , 2008, , .	2.6	12
86	Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. <i>International Journal of Oncology</i> , 2008, , .	3.3	2
87	The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. <i>Oncology Reports</i> , 2008, 19, 1039-43.	2.6	34
88	Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. <i>European Journal of Cancer</i> , 2007, 43, 2124-2133.	2.8	128
89	Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. <i>Molecular and Cellular Endocrinology</i> , 2007, 264, 44-49.	3.2	45
90	BCG-infected adherent mononuclear cells release cytokines that regulate group 1 CD1 molecule expression. <i>International Immunopharmacology</i> , 2007, 7, 321-332.	3.8	5

#	ARTICLE	IF	CITATIONS
91	Incidence of Parenterally Transmitted Acute Viral Hepatitis Among Healthcare Workers in Italy. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 629-632.	1.8	7
92	Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?. <i>Pharmacological Research</i> , 2007, 55, 359-369.	7.1	61
93	Corticotropin-releasing hormone receptor-1 in human endometrial cancer. <i>Oncology Reports</i> , 2006, 15, 375.	2.6	1
94	Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2006, 594, 63-77.	1.0	15
95	Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. <i>FASEB Journal</i> , 2006, 20, 1709-1711.	0.5	97
96	Corticotropin-releasing hormone receptor-1 in human endometrial cancer. <i>Oncology Reports</i> , 2006, 15, 375-9.	2.6	9
97	N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor- κ B DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity. <i>Molecular Pharmacology</i> , 2005, 67, 572-581.	2.3	11
98	Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. <i>International Journal of Oncology</i> , 2005, 26, 415.	3.3	6
99	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. <i>International Journal of Oncology</i> , 2005, 27, 525.	3.3	15
100	Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. <i>European Journal of Cancer</i> , 2005, 41, 2948-2957.	2.8	37
101	PARP-1 inhibition to treat cancer, ischemia, inflammation. <i>Pharmacological Research</i> , 2005, 52, 1-4.	7.1	30
102	Chemopotentialiation by PARP inhibitors in cancer therapy. <i>Pharmacological Research</i> , 2005, 52, 25-33.	7.1	170
103	Clinical perspectives of PARP inhibitors. <i>Pharmacological Research</i> , 2005, 52, 109-118.	7.1	130
104	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. <i>International Journal of Oncology</i> , 2005, 27, 525-35.	3.3	13
105	Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity. <i>Medicinal Chemistry Reviews Online</i> , 2004, 1, 141-150.	0.1	3
106	Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy. <i>Journal of Medical Virology</i> , 2004, 74, 216-220.	5.0	84
107	Primary cultures of microglial cells for testing toxicity of anticancer drugs. <i>Toxicology Letters</i> , 2004, 148, 91-94.	0.8	14
108	Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells. <i>Endocrinology</i> , 2003, 144, 2822-2828.	2.8	23

#	ARTICLE	IF	CITATIONS
109	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. <i>Molecular Pharmacology</i> , 2003, 63, 192-202.	2.3	42
110	Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. <i>Clinical Cancer Research</i> , 2003, 9, 5370-9.	7.0	160
111	A Novel Method for Monitoring Response to Chemotherapy Based on the Detection of Circulating Cancer Cells: A Case Report. <i>Journal of Chemotherapy</i> , 2002, 14, 412-416.	1.5	7
112	CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway. <i>Endocrinology</i> , 2002, 143, 807-813.	2.8	64
113	Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. <i>Blood</i> , 2002, 99, 2241-2244.	1.4	83
114	Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents. <i>Current Medicinal Chemistry</i> , 2002, 9, 1285-1301.	2.4	52
115	Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. <i>Pharmacological Research</i> , 2002, 45, 73-85.	7.1	134
116	Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine. <i>International Immunopharmacology</i> , 2002, 2, 641-651.	3.8	5
117	Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells. <i>Glia</i> , 2002, 40, 44-54.	4.9	61
118	Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. <i>International Journal of Cancer</i> , 2002, 100, 119-121.	5.1	6
119	Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 217-224.	2.3	16
120	CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway. <i>Endocrinology</i> , 2002, 143, 807-813.	2.8	20
121	Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. <i>Journal of Cell Science</i> , 2002, 115, 1643-1649.	2.0	26
122	Influence of <i>Mycobacterium bovis</i> Bacillus Calmette Guérin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. <i>Infection and Immunity</i> , 2002, 70, 2739-2739.	2.2	0
123	Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. <i>Journal of Cell Science</i> , 2002, 115, 1643-9.	2.0	20
124	Bacillus Calmette-Guerin Down-Regulates CD1b Induction by Granulocyte-Macrophage Colony Stimulating Factor in Human Peripheral Blood Monocytes. <i>Journal of Chemotherapy</i> , 2001, 13, 52-58.	1.5	9
125	Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 361-369.	2.3	26
126	Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. <i>Cell Death and Differentiation</i> , 2001, 8, 457-469.	11.2	28

#	ARTICLE	IF	CITATIONS
127	Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. <i>Cell Death and Differentiation</i> , 2001, 8, 817-828.	11.2	39
128	Influence of <i>Mycobacterium bovis</i> Bacillus Calmette Gueïrin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. <i>Infection and Immunity</i> , 2001, 69, 7461-7470.	2.2	21
129	hMSH3 overexpression and cellular response to cytotoxic anticancer agents. <i>Carcinogenesis</i> , 2001, 22, 1131-1137.	2.8	11
130	Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. <i>Leukemia</i> , 2000, 14, 1451-1459.	7.2	19
131	Staurosporine Increases Carcinoembryonic Antigen Expression in a Human Colon Cancer Cell Line. <i>Journal of Chemotherapy</i> , 2000, 12, 167-172.	1.5	6
132	Telomerase as a potential anticancer target: growth inhibition and genomic instability. <i>Drug Resistance Updates</i> , 2000, 3, 3-6.	14.4	1
133	Clinical applications of telomerase in cancer treatment. <i>Drug Resistance Updates</i> , 2000, 3, 161-170.	14.4	6
134	In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers. <i>Leukemia</i> , 1999, 13, 222-229.	7.2	11
135	Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. <i>Leukemia</i> , 1999, 13, 901-909.	7.2	56
136	Mutation of the mismatch repair genes MSH2 and MSH6 in a human T-cell leukemia line tolerant to methylating agents. , 1998, 23, 159-166.		31
137	Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. <i>Cancer Immunology, Immunotherapy</i> , 1998, 47, 157-166.	4.2	10
138	Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen. <i>Life Sciences</i> , 1998, 63, 985-994.	4.3	10
139	Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. <i>Melanoma Research</i> , 1998, 8, 323-328.	1.2	11
140	Rifampin Increases Cytokine-Induced Expression of the CD1b Molecule in Human Peripheral Blood Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 550-554.	3.2	31
141	Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis. <i>Molecular Pharmacology</i> , 1998, 54, 334-341.	2.3	233
142	CYTOKINE-INDUCED EXPRESSION OF CD1b MOLECULES BY PERIPHERAL BLOOD MONOCYTES: INFLUENCE OF 3- ² -AZIDO-3- ² -DEOXYTHYMIDINE. <i>Pharmacological Research</i> , 1997, 35, 135-140.	7.1	9
143	Inhibition of O ⁶ -Alkylguanine DNA-Alkyltransferase or Poly(ADP-ribose) Polymerase Increases Susceptibility of Leukemic Cells to Apoptosis Induced by Temozolomide. <i>Molecular Pharmacology</i> , 1997, 52, 249-258.	2.3	53
144	Development of a Novel In Vitro Chemosensitivity Assay: Telomerase as a Possible Marker of Tumor Cell Survival. <i>Journal of Chemotherapy</i> , 1996, 8, 394-398.	1.5	5

#	ARTICLE	IF	CITATIONS
145	Cisplatin Increases Sensitivity of Human Leukemic Blasts to Triazene Compounds. <i>Journal of Chemotherapy</i> , 1995, 7, 224-229.	1.5	26
146	Chimeric Molecules between Keratinocyte Growth Factor and Basic Fibroblast Growth Factor Define Domains That Confer Receptor Binding Specificities. <i>Journal of Biological Chemistry</i> , 1995, 270, 29813-29818.	3.4	37
147	In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity. <i>International Journal of Immunopharmacology</i> , 1993, 15, 1-10.	1.1	3
148	Emergence of Double-Positive CD4/CD8 Cells from Adult Peripheral Blood Mononuclear Cells Infected with Human T Cell Leukemia Virus Type I (HTLV-I). <i>Cellular Immunology</i> , 1993, 149, 376-389.	3.0	33
149	Transient HTLV-I Infection of a Human Glioma Cell Line Following Cell-Free Exposure. <i>Virology</i> , 1993, 197, 767-769.	2.4	8
150	Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. <i>International Journal of Oncology</i> , 1992, 32, 1293-1303.	3.3	18
151	Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of <i>Xenopus laevis</i> oocytes in response to insulin and ras p21. <i>Journal of Biological Chemistry</i> , 1991, 266, 6825-9.	3.4	57
152	Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon. <i>British Journal of Cancer</i> , 1988, 57, 481-488.	6.4	18
153	Effect of hydrocortisone on human natural killer activity and its modulation by beta interferon. <i>International Journal of Immunopharmacology</i> , 1988, 10, 687-694.	1.1	9
154	Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV). <i>Leukemia Research</i> , 1985, 9, 349-355.	0.8	21